Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

Inclusion Criteria: * Diagnosis of Type 2 diabetes mellitus * Inadequate glycemic control on a stable dose (at least 2 months prior to screening) of pioglitazone at 30 or 45 mg/day, with or without one or two other oral antidiabetic medications \[metformin or a sulfonylurea, or dipeptidyl peptidase (DPP-IV) inhibitor\] * Hemoglobin A1c (HbA1c) \>= 7.5% and =\< 9.5% at screening * Fasting plasma glucose =\<240 mg/dL at randomization (Week 0/Day 1). * Male or female \>= 18 years of age. * Women of childbearing potential must be using an adequate method of contraception as detailed per-protocol * Fasting C-peptide level \>0.5 ng/mL at screening * Clinically stable in regards to medical conditions other than type 2 diabetes * Concomitant medications are at stable doses for at least 30 days prior to enrollment, and are not anticipated to need adjustment during the study period Exclusion Criteria: * History of Type 1 diabetes and/or history of ketoacidosis * History of bowel obstruction * History of hypertriglyceridemia-induced pancreatitis * Fasting serum triglyceride concentration \>500 mg/dL * History of dysphagia, swallowing disorders, gastroparesis, other gastrointestinal motility disorders, major gastrointestinal surgery * History of insulin use \>= 2 weeks duration during the previous 3 months or a total of \>2 months insulin therapy at any time prior to screening * Treatment with bile acid sequestrants, including colesevelam within 3 months prior to screening * Female subject who is pregnant or breastfeeding * History of unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack, or any revascularization within 6 months prior to screening